Effectiveness of tisagenlecleucel versus real-world standard of care in relapsed/refractory follicular lymphoma.
| Title: | Effectiveness of tisagenlecleucel versus real-world standard of care in relapsed/refractory follicular lymphoma. |
|---|---|
| Authors: | Hao Y; Novartis Pharmaceuticals Corporation, East Hanover, NJ 07936, USA.; Current affiliation: Gilead Sciences, Foster City, CA 94404, USA.; Hsu WC; Genesis Research, Hoboken, NJ 07030, USA.; Parzynski CS; Genesis Research, Hoboken, NJ 07030, USA.; Degtyarev E; Novartis Pharma AG, CH-4056, Basel, Switzerland.; Hampson LV; Novartis Pharma AG, CH-4056, Basel, Switzerland.; Masood A; Novartis Pharmaceuticals Corporation, East Hanover, NJ 07936, USA.; Wu WH; Genesis Research, Hoboken, NJ 07030, USA. |
| Source: | Journal of comparative effectiveness research [J Comp Eff Res] 2023 Jul; Vol. 12 (7), pp. e220173. Date of Electronic Publication: 2023 Jun 22. |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't |
| Language: | English |
| Journal Info: | Publisher: Becaris Publishing Country of Publication: England NLM ID: 101577308 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2042-6313 (Electronic) Linking ISSN: 20426305 NLM ISO Abbreviation: J Comp Eff Res Subsets: MEDLINE |
| Imprint Name(s): | Publication: 2023- : Royston, UK : Becaris Publishing; Original Publication: London : Future Medicine |
| MeSH Terms: | Lymphoma, Follicular*/therapy; Humans ; Retrospective Studies ; Standard of Care ; Neoplasm Recurrence, Local ; Receptors, Antigen, T-Cell |
| Abstract: | Aim: To contextualize the effectiveness of tisagenlecleucel versus real-world standard of care (SoC) in relapsed/refractory follicular lymphoma. Materials & methods: A retrospective indirect matched comparison study using data from the phase II ELARA trial and the US Flatiron Health Research Database. Results: Complete response rate was 69.1 versus 17.7% and the overall response rate was 85.6 versus 58.1% in tisagenlecleucel versus SoC, post weighting by odds. For overall survival, an estimated reduction in the risk of death was observed in favor of tisagenlecleucel over SoC. The hazard ratio for progression-free survival was 0.45 (95% CI: 0.26, 0.88), and for time-to-next treatment was 0.34 (95% CI: 0.15, 0.78) with tisagenlecleucel versus SoC. Conclusion: A consistent trend toward improved efficacy end points was observed in favor of tisagenlecleucel versus SoC. |
| References: | Cancer. 2023 May 15;129(10):1465-1466. (PMID: 37088993); Lancet Oncol. 2022 Jan;23(1):91-103. (PMID: 34895487); Blood. 2016 Aug 25;128(8):1112-20. (PMID: 27418643); Eur J Haematol. 2019 Sep;103(3):152-163. (PMID: 31270855); Ann Oncol. 2022 Apr;33(4):376-383. (PMID: 35026413); J Natl Compr Canc Netw. 2021 Nov;19(11):1218-1230. (PMID: 34781267); Blood Adv. 2022 Nov 22;6(22):5835-5843. (PMID: 35973192); Nat Med. 2022 Feb;28(2):325-332. (PMID: 34921238); Leuk Lymphoma. 2023 Apr;64(4):761-775. (PMID: 37061956); Blood. 2022 Aug 25;140(8):851-860. (PMID: 35679476); Clin Pharmacol Ther. 2022 Jan;111(1):168-178. (PMID: 34197637); Expert Rev Anticancer Ther. 2002 Oct;2(5):485-93. (PMID: 12382517); Clin Lymphoma Myeloma Leuk. 2020 Apr;20(4):e184-e194. (PMID: 31956071); J Clin Oncol. 2015 Aug 10;33(23):2516-22. (PMID: 26124482); Expert Opin Pharmacother. 2022 Feb;23(3):295-301. (PMID: 34904909); Am J Hematol. 2020 Mar;95(3):316-327. (PMID: 31814159); J Clin Oncol. 2014 Sep 20;32(27):3059-68. (PMID: 25113753); J Clin Oncol. 2013 Apr 20;31(12):1506-13. (PMID: 23530110); Am J Epidemiol. 2016 Apr 15;183(8):758-64. (PMID: 26994063); Eur J Epidemiol. 2017 Jun;32(6):495-500. (PMID: 28748498); Cancer Manag Res. 2021 May 14;13:3935-3952. (PMID: 34017197); Stat Sci. 2010 Feb 1;25(1):1-21. (PMID: 20871802); Ann Oncol. 2013 Mar;24(3):561-76. (PMID: 23175624); Lancet Oncol. 2022 Aug;23(8):1055-1065. (PMID: 35803286); Drugs. 2022 Jul;82(11):1229-1234. (PMID: 35947358); Clin Adv Hematol Oncol. 2022 Jun;20(6):394-396. (PMID: 35731611) |
| Grant Information: | Novartis Pharmaceuticals Corporation |
| Contributed Indexing: | Keywords: CAR-T; anti-CD20; follicular lymphoma; non-Hodgkin lymphoma; real-world evidence; refractory; relapsed; standard of care; tisagenlecleucel |
| Substance Nomenclature: | Q6C9WHR03O (tisagenlecleucel); 0 (Receptors, Antigen, T-Cell) |
| Entry Date(s): | Date Created: 20230622 Date Completed: 20230703 Latest Revision: 20260127 |
| Update Code: | 20260130 |
| PubMed Central ID: | PMC10508300 |
| DOI: | 10.57264/cer-2022-0173 |
| PMID: | 37345672 |
| Database: | MEDLINE |
Journal Article; Research Support, Non-U.S. Gov't